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ABSTRACT
Background: Griseofulvin, an oral nontoxic antifungal drug, has been re-
ported to possess anticancer effect in human cancer cells, while the mechanisms are 
not completely understood.
Objective: The aim of this study was to investigate the cytotoxic effect of 
griseofulvin on K562 cells and to understand its underlying molecular pathways.
Methods: K562 cells were treated with griseofulvin at different concentrations 
for 24 hours, and the inhibition effect of griseofulvin on K562 cell proliferation was 
assessed by tetrazolium salt colorimetric assay. Apoptosis was assessed by examining 
nuclear morphology and quantifying phosphatidylserine externalization, and altera-
tions in cellular morphology were analyzed by laser scanning confocal microscopy for 
fluorescent analysis. Flow cytometry was used in the analysis of cell cycle, mitochon-
drial membrane potential, and caspase pathways.
Results: Griseofulvin could inhibit the growth of K562 cells in a dose- 
dependent manner with a mean (SD) inhibitory concentration of 50% value of 15.38 
(1.35) μg/mL compared with untreated controls. Apoptosis was induced in K562 cells 
(38.35% [2.73%]; P < 0.01) by griseofulvin with the observation of both an increase in 
phosphatidylserine level and accumulation of chromatin nucleation in griseofulvin-
treated cells. In addition, cell-cycle analysis using propidium iodide staining suggested 
a significant G2/M accumulation (increase from mean 17.64% [4.49%] to 48.29 [1.89%]; 
P < 0.01) as a result of griseofulvin treatment. Flow cytometry analysis found that 
griseofulvin treatment was associated with the depolarization of the mitochondrial 
membrane in K562 cells. Furthermore, increased activities of caspase-3 by 22.15-fold 
(P < 0.01) and caspase-9 by 16.73-fold (P < 0.01) were observed in K562 cells after 
griseofulvin treatment compared with the untreated control; a decrease of caspase-8 
activity was also observed, but the change was not statistically significant.
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Conclusions: These findings suggest that griseofulvin inhibited growth of 
K562 cells and induced cell apoptosis through cell-cycle arrest and mitochondrial 
membrane potential decrease as well as caspase-3 and -9 activation. Further testing is 
needed to evaluate the potential of griseofulvin as a candidate in the chemotherapy 
of hematologic malignancies. (Curr Ther Res Clin Exp. 2010;71:384–397) © 2010 
Elsevier HS Journals, Inc.
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INTRODUCTION
Griseofulvin is an oral nontoxic antifungal drug derived from several species of Penicillium, 
and has been used for many years in the treatment of tinea capitis and other dermato-
phyte infections.1,2 Griseofulvin has been found to inhibit the growth of fungal cells 
through selectively inhibiting microtubule depolymerization and inducing abnormal 
cell mitosis and blocking the cells at the G2/M phase of the cell cycle.3,4 Recently, 
griseofulvin has been attracting considerable interest as a potential anticancer drug 
owing to its low toxicity and efficacy in antiproliferation of different types of cancer 
cells, including colon adenocarcinoma and leukemia.5–8 Griseofulvin treatment has 
also been proposed to inhibit tumor growth in athymic mice when combined with 
nocodazole, and it has been found to induce apoptosis in cancer cell lines and selec-
tively kill cancer cells while sparing normal healthy cells.6,7
Griseofulvin is known to block cell-cycle progression at G2/M in colon cancer cells 
and it promotes G2/M arrest by inducing abnormal mitotic spindle formation, activat-
ing cyclin B1/cdc2 kinase activity and downregulating myt-1 protein expression.5–7 
Griseofulvin induces apoptosis potentially through the caspase-3 pathway, while B cell 
lymphoma-2 (BCL-2) hyperphosphorylation and inhibition of the normal BCL-2 
function associated with BCL-2 associated X protein are also proposed to be involved 
in this process.6 Griseofulvin also induces multipolar spindles by inhibiting cen-
trosome coalescence and subsequent cell death in tumor cell lines.7 The inhibition of 
centrosome clustering by griseofulvin was not restricted to mitotic cells but did occur 
during interphase of the cell cycle. Activation of the nuclear factor-kappa B (NF-κB) 
pathway and phosphorylation of BCL-2 might be involved in G2/M cell-cycle arrest 
in human promyelocytic leukemia cells (HL-60),8 while the signal pathways involved 
in griseofulvin-induced apoptosis are still not fully understood.
Previous studies in human colon adenocarcinoma grade II (HT-29) cells and human 
acute myelogenous leukemia HL-60 cells have indicated that the anticancer effect of 
griseofulvin might vary in different human cancers.5–8 For example, griseofulvin-
induced apoptosis is reported to occur through caspase-3 activation in HT-29 cells,6 
while occurring through activation of the NF-κB pathway in HL-60 cells.8 Further-
more, griseofulvin-induced G2/M cell-cycle arrest and apoptosis could be completely 
reversed in HL-60 cells with the treatment of tosyl phenylalanyl chloromethyl ketone, 
a serine protease inhibitor, but not in HT-29 cells.9 Caspases have been found to play 
a pivotal role in the terminal execution phase of apoptosis induced by diverse stimuli. 
Caspase-3 is classically categorized as executioner caspase, and caspase-8 and -9 as 
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initiator caspases according to their function and their sequences of activation.10 There-
fore, it may be worthy to investigate whether these caspase components are also involved 
in griseofulvin-induced apoptosis in leukemia cells. In the present study, we examined 
the antileukemic effects of griseofulvin in leukemia cells and investigated the role of 
capase-3, -8, and -9 pathways in the griseofulvin-induced apoptosis in K562 cells.
MATERIALS AND METHODS
Cell Culture and Treatment Agent
K562 cells were maintained in a nutrient medium (RPMI-1640, Gibco, London, 
United Kingdom) and supplemented with 10% fetal bovine serum (Gibco) at 37°C 
in a 95% air/5% CO2 atmosphere. Griseofulvin (Sigma-Aldrich Chemicals, St. Louis, 
Missouri) stock solution was prepared in dimethyl sulfoxide and stored at –20°C.
Cell Growth Inhibition Assay
K562 cells were plated in 96-well plates in 200 μL of the medium. About 
10,000 K562 cells were seeded in each well of a 96-microwell plate and treated with 
various concentrations of griseofulvin (5, 10, 20, and 40 μg/mL). A control group was 
left untreated. After 24 hours, the inhibitory concentration of 50% (IC50) value was 
calculated by the MTT (methyl-thiazoldiphenyl tetrazolium) method. Twenty micro-
liters of medium containing 10% fetal bovine serum and 5-mg/mL MTT (Sigma-
Aldrich Chemicals) were added to each well. The plates were then incubated at 37°C 
for 4 hours. The precipitated formazan was dissolved in 100 μL of dimethyl sulfoxide. 
Absorbance at 570 nm of the mixture was measured using a microplate enzyme-
linked immunosorbent assay reader. Cell survival rate was calculated as follows:
Percentage of survival = (mean experimental absorbance/mean control absorbance) × 100%.
Assessment of Nuclear Apoptotic Morphology
Staining with Hoechst 33,258 (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbo-
cyanine) (Sigma-Aldrich Chemicals) was used to identify apoptotic nuclei. K562 cells 
were collected and fixed, washed twice with phosphate-buffered saline (PBS), and 
stained with Hoechst 33,258 staining solution according to the manufacturer’s in-
structions (Apoptosis, Hoechst Staining Kit, Beyotime Biotechnology, China). Stained 
nuclei were observed under a laser scanning confocal microscope (TCS-SP2, Leica 
Microsystems, Heidelberg, Germany).
Cell-Cycle Analysis
Propidium iodide (PI) (Sigma-Aldrich Chemicals) staining and flow cytometry 
(FCM) were used to determine the stage of the cell cycle. Cells (1 × 106) were treated 
with or without griseofulvin for 24 hours at 37°C. Cells were then collected and 
washed twice with PBS buffer, suspended in 70% ice-cold ethanol, and stored 
overnight at –20°C. The next day, samples were washed with PBS and incubated with 
25-μg/mL ribonuclease A (Fermentas, Burlington, Canada) at 37°C for 30 minutes. 
Next, the cells were stained with 50 μg/mL of PI. Samples were analyzed on a flow 
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cytometer (FACScan, Becton, Dickinson and Company, Franklin Lakes, New Jersey) 
using cell analysis software to determine the population of cells in each cycle phase.
Apoptosis Assay
Cell apoptosis was evaluated by detecting phosphatidylserine externalization using 
FCM with a 2-color analysis of fluorescein isothiocyanate (FITC)–labeled Annexin 
V/PI double-staining as previously reported.11 Briefly, cells were treated with or with-
out griseofulvin, then washed twice with PBS and resuspended in 100 μL of incuba-
tion buffer containing Annexin V (Roche, Penzberg, Germany) and PI according to 
the manufacturer’s instructions. The samples were incubated at room temperature for 
10 minutes and then analyzed by FCM.
Assessment of Mitochondrial Membrane Potential
Changes in mitochondrial membrane potential (MMP) were measured using FCM 
staining with JC-1 (5,5'6,6'-tetracholoro-1,1',3,3'-tetraethylbenzimi-dazolyl-
carbocyanine iodide) (Molecular Probes, Eugene, Oregon). JC-1 is a cationic dye that 
exhibits potential-dependent accumulation in mitochondria, shown by a fluorescence 
emission shift from green (525 ± 10 nm) to red (610 ± 10 nm). Mitochondrial mem-
brane depolarization was specifically indicated by a decrease in the red-to-green 
fluorescence intensity ratio, as reported in previous studies.12,13 Briefly, the harvested 
cells (2×106) were suspended in 0.5 mL of medium containing 10 μg/mL of JC-1 for 
10 minutes at 37°C. Samples (1×104 cells/sample) were analyzed by a 4-color cytom-
eter (FACSCalibur, Becton, Dickinson and Company) using an argon laser (488 nm).
Flow Cytometric Analysis of Caspase Activity
The active forms of caspase-3, -8, and -9 were quantified by direct staining of cells with 
an FITC-conjugated rabbit antiactive caspase monoclonal antibody (BioVision Company, 
Mountain View, California) followed by cytometric analysis. Briefly, cells were fixed with 
1% formaldehyde for 15 minutes at 4°C, washed twice with PBS, permeabilized with 
0.1% Triton X-100 in PBS for 15 minutes at 4°C, and incubated with goat serum. Cells 
were then stained with FITC-conjugated antiactive caspase antibody. After washing with 
PBS, cells were again fixed with 1% formaldehyde and analyzed by 4-color cytometer.
Statistical Analysis
All experiments were performed in triplicate. Data presented are the mean (SD) of 
results from the 3 independent experiments with similar patterns. Statistical signifi-
cance of the difference between treated and untreated groups was determined by the 
unpaired t test. P < 0.05 was considered statistically significant.
RESULTS
K562 Cell Growth
K562 cells were treated with griseofulvin at different concentrations (5, 10, 20, 
and 40 μg/mL) for 24 hours to examine the growth inhibitory effects of griseofulvin, 
and cell growth was evaluated by MTT assay. The viability of K562 cells was inhib-
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ited by griseofulvin treatment in a dose-dependent manner, with the mean (SD) IC50 
value being 15.38 (1.35) μg/mL (Figure 1A). This dose of griseofulvin at 15 μg/mL 
was then used to treat K562 cells for the remaining experiments in this study.
Irregular staining of cell nuclei was observed in griseofulvin-treated cells (Figure 
1C), when compared with control cells without griseofulvin treatment (Figure 1B). 
The irregular staining of cell nuclei, which was a result of chromatin condensation and 
nuclear fragmentation, demonstrated the apoptosis in the griseofulvin-treated cells.
Cell-Cycle Arrest in the G2/M Phase
Figure 2 shows the results of FCM analysis in which cell-cycle distribution was 
changed in griseofulvin-treated K562 cells and cellular proliferation was inhibited 
and arrested at the G2/M phase. Mean (SD) cells in the sub-G1 phase increased from 
1.88% (0.41%) (control) (Figure 2A) to 19.20% (1.88%) with griseofulvin treat-
ment (Figure 2B). Specifically, cells in the G2/M phase increased from 17.64% 
(4.49%) (control) to 48.29% (1.89%) with griseofulvin treatment. A decrease in the 
percentage of cells was also observed in the S phase from 51.43% (3.61%) to 29.93% 
(2.35%) (P < 0.01) in griseofulvin-treated cells (Table I).
K562 Cell Apoptosis
As shown in Figure 3A and 3B, the dual parametric dot plots combining annexin 
V-FITC and PI fluorescence show the viable cell population (lower left quadrant, an-
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Figure 1.  Griseofulvin inhibits the growth of K562 cells. (A) Cytotoxic effects of griseofulvin 
on K562 cells. Cells were treated for 24 hours in the presence of different con-
centrations of griseofulvin. Cytotoxicity was determined by methyl-thiazoldiphenyl 
tetrazolium assay. Results are the mean (SD) of 3 independent experiments.
(continued)
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nexin V–/PI–), the early apoptotic cells (lower right quadrant, annexin V+/PI–), and 
the late apoptotic cells (upper right quadrant, annexin V+/PI+). In untreated K562 
cells, the mean (SD) percentage of cells at the early phase of apoptosis (lower right 
quadrant) and the late phase of apoptosis (upper right quadrant) was 5.11% (0.68%) 
(Figures 3A and 3C). After treatment with griseofulvin, the percentage of apoptotic 
cells increased to 38.35% (2.73%) (P < 0.01) (Figure 3B and 3C) (Table II).
Figure 1  (continued). Griseofulvin inhibits the growth of K562 cells. (B) Diffusely stained 
intact nuclei were observed in K562 cells without griseofulvin treatment. 
(C) After K562 cells were treated with griseofulvin 15 μg/mL for 24 hours, apop-
totic cells showed condensed chromatin and apoptotic bodies can be seen. N = 
normal cells. The apoptotic cells are indicated with the arrows. 
B
C
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Figure 2.  Alteration of cell-cycle distribution induced by griseofulvin (15 μg/mL for 24 hours). 
Nuclear DNA was labeled by propidium iodide and determined by single-label 
flow cytometry. Compared with the control, griseofulvin was associated with 
inducing G2/M arrest (increasing G2/M population). (A) Control K562 cells 
(untreated). (B) K562 cells treated with griseofulvin (15 μg/mL for 24 hours).
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Mitochondrial Membrane Potential
Griseofulvin-induced MMP and mitochondrial depolarization both could be iden-
tified by the decrease in the red/green fluorescence intensity ratio.11,12 In this study, a 
significant decrease in the mean (SD) value of the red/green fluorescence intensity 
ratio was observed from 9.27 (0.93) (control) to 6.72 (1.57) in K562 cells after 
griseofulvin treatment (P < 0.05) (Figure 4A) (Table III).
Caspase-3 and -9 Apoptosis Involvement
As shown in Figure 4B, the caspase-3 activity was increased by 22.15-fold (P < 
0.01) in griseofulvin-treated K562 cells, and the caspase-9 activity was increased by 
16.73-fold (P < 0.01) compared with control cells. A decrease in caspase-8 activity 
was observed in K562 cells after griseofulvin treatment; however, this change was not 
statistically significant (Figure 4B) (Table IV).
DISCUSSION
The present study was undertaken to examine the antiproliferative effect of griseoful-
vin and the mechanisms involved in the griseofulvin-induced G2/M cell-cycle arrest 
and apoptosis in human leukemic K562 cells. We found that griseofulvin inhibited 
the proliferation of K562 cells in a dose-dependent manner. The results also suggest 
that griseofulvin-induced apoptosis in K562 cells involves cell-cycle arrest in the 
G2/M phase, a decrease in MMP, and an increase in activated caspase-3 and -9.
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Figure 2.  (continued). Alteration of cell-cycle distribution induced by griseofulvin (15 μg/
mL for 24 hours). Nuclear DNA was labeled by propidium iodide and determined 
by single-label flow cytometry. Compared with the control, griseofulvin was as-
sociated with inducing G2/M arrest (increasing G2/M population). (C) Graphic 
representation of the alteration of cell-cycle distribution induced by griseofulvin. 
*P < 0.01 versus control.
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Cell-cycle control is the major regulatory mechanism of cell growth. Many cyto-
toxic agents and/or DNA damaging agents arrest the cell cycle at the G1, S, or G2/M 
phase before inducing apoptotic cell death.14,15 Disturbance of the cancer-cell cycle is 
one therapeutic target for the development of new anticancer drugs.16 It has been 
found that cell-cycle arrest may result in apoptosis due to the existence of cell-cycle 
checkpoint and feedback control.17 However, several lines of evidence have suggested 
that some anticancer drugs induce apoptosis via signaling pathways independent of 
cell-cycle arrest.18 In the present study, the results of FCM analysis suggested that 
a significant accumulation occurred at the G2/M phase in K562 cells after griseoful-
vin treatment, which was associated with a significant decrease in cells at the G1 and 
S phases.
Caspases are central executioners of apoptosis.19 Currently, 2 major apoptotic sig-
naling pathways have been defined. The first one, the mitochondria-dependent path-
way, responds to extracellular cues and internal insults such as DNA damage.20 The 
second apoptotic pathway is triggered by death-receptor superfamily members 
through the activation of caspase-8. Death-receptor and mitochondrial pathways con-
verge at the level of caspase-3, while it is feasible to differentiate them by evaluating 
the activities of caspase-8 and -9.21,22 In the previous study in HL-60 leukemic cells, 
it was reported that griseofulvin-induced apoptosis through activation of the NF-κB 
pathway in HL-60 cells.8 In the present study, we found evidence that griseofulvin-
induced apoptosis in K562 leukemic cells was mediated by a caspase-dependent path-
way, with observations of griseofulvin treatment inducing the increase of caspase-3 and 
-9 activity by 22.15- and 16.73-fold, respectively. It has been reported that the de-
crease of MMP occurs early in mitochondria-mediated apoptosis, and loss of MMP 
alters mitochondrial permeability, which triggers the opening of the permeability 
transition pore and has been implicated as a critical stage in apoptosis.23 Previous 
studies have suggested that loss of MMP and release of apoptogenic factors, such as 
cytochrome C and apoptosis-inducing factor, from the mitochondria into the cytosol, 
are associated with apoptosis induced by chemotherapeutic drugs.24,25 In the present 
study, our results indicate that the treatment with griseofulvin might dramatically 
induce loss of MMP in K562 cells, suggesting that griseofulvin-induced apoptosis 
might occur due to the loss of MMP.
Table I.  Effects of griseofulvin on cell-cycle distribution of K562 cells. Data are mean 
(SD) percentage.
 Griseofulvin 
Cell Cycle (15 μg/mL) Control P*
Sub-G1 19.20 (1.88) 1.87 (0.40) <0.01
G0/G1 21.77 (2.37) 30.93 (0.91) <0.01
S 29.93 (2.35) 51.43 (3.61) <0.01
G2/M 48.29 (1.89) 17.64 (4.49) <0.01
*Versus control.
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Figure 3.  Detection of griseofulvin-induced apoptosis in K562 cells. Flow cytometry analy-
sis of phosphatidylserine externalization (annexin V binding) and cell membrane 
integrity (propidium iodide staining) in K562 cells. (A) Control K562 cells (un-
treated). (B) K562 cells treated with griseofulvin (15 μg/mL for 24 hours).
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These data suggest that griseofulvin induces apoptosis in K562 cells through 
3 mechanisms: (1) inhibition of cellular proliferation by arresting cells at the G2/M cell 
phase; (2) decreasing MMP; and (3) activating caspase-3 and -9. These results provide 
evidence that griseofulvin might have a promising role as a therapeutic agent in the 
chemotherapy of leukemia. However, the present findings were only obtained from an 
in vitro study of K562 cells and limited to drawing conclusions for the antiprolifera-
tive effect of griseofulvin in human hematologic malignancies in vivo. Further studies 
to investigate the details of mechanisms of activating caspase-3 and -9 pathways in 
griseofulvin-treated leukemia cells would be desirable.
CONCLUSIONS
These findings suggest that griseofulvin inhibited growth of K562 cells and induced cell 
apoptosis through cell-cycle arrest and MMP decrease as well as caspase-3 and -9 activa-
tion. Further testing is needed to evaluate the potential of griseofulvin as a candidate in 
the chemotherapy of hematologic malignancies.
Figure 3  (continued). Detection of griseofulvin-induced apoptosis in K562 cells. Flow cy-
tometry analysis of phosphatidylserine externalization (annexin V binding) and 
cell membrane integrity (propidium iodide staining) in K562 cells. (C) Graphic 
representation of the flow cytometric analysis of K562 cells’ apoptosis. *P < 0.01 
versus control.
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Table II.  The effect of griseofulvin on the apoptosis of K562 cells. Data are mean (SD) 
percentage.
 Griseofulvin 
Variable (15 μg/mL) Control P
Apoptotic cells 38.35 (2.73) 5.11 (0.68) <0.01
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Figure 4.  Effects of griseofulvin on the changes in mitochondrial membrane potential and 
the activation of caspases in K562 cells. Each value is expressed as mean 
(SD). (A) The K562 cells were treated with griseofulvin for 24 hours at 15 μg/mL. 
Compared with the control group, griseofulvin caused a decrease in the ratio of 
red to green in K562 cells. (B) Active caspase-positive cells were determined by 
flow cytometry after staining with fluorescein isothiocyanate–conjugated rabbit 
antiactive caspase monoclonal antibody. The number of caspase-positive cells of 
the control groups was considered to be one and the relative caspase-positive 
cells of the griseofulvin-treated group was expressed as the fold-change com-
pared with that of the control group. *P < 0.01 versus control.
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